219,747 Shares in CareDx, Inc (NASDAQ:CDNA) Purchased by Next Century Growth Investors LLC

Next Century Growth Investors LLC purchased a new position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 219,747 shares of the company's stock, valued at approximately $4,705,000. Next Century Growth Investors LLC owned about 0.41% of CareDx as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Quarry LP bought a new stake in CareDx during the third quarter valued at $27,000. Thompson Davis & CO. Inc. lifted its stake in shares of CareDx by 6.3% in the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock valued at $344,000 after purchasing an additional 950 shares during the period. Legal & General Group Plc boosted its position in shares of CareDx by 1.3% during the 4th quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock valued at $1,922,000 after purchasing an additional 1,118 shares in the last quarter. Sterling Capital Management LLC grew its stake in CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after purchasing an additional 1,126 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in CareDx by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock worth $406,000 after purchasing an additional 1,151 shares in the last quarter.

CareDx Trading Down 2.9 %

CareDx stock traded down $0.52 during trading on Thursday, hitting $17.70. 256,871 shares of the company were exchanged, compared to its average volume of 854,967. The business's 50 day moving average is $19.98 and its 200 day moving average is $22.56. CareDx, Inc has a 52 week low of $7.42 and a 52 week high of $34.84. The company has a market capitalization of $981.04 million, a P/E ratio of -6.58 and a beta of 2.18.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. Equities analysts expect that CareDx, Inc will post -0.9 EPS for the current year.

Analysts Set New Price Targets

CDNA has been the topic of a number of research analyst reports. HC Wainwright cut their price target on CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. The Goldman Sachs Group cut their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded CareDx from an "underweight" rating to an "equal weight" rating and decreased their price objective for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. Finally, Stephens reaffirmed an "overweight" rating and set a $40.00 target price on shares of CareDx in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.